BioSpace News Archive

DUBAI, United Arab Emirates, Obese people are seldom prone to health implications arising from increasing caseload for varicose veins in their body.

Automated Microplate Handling Systems Market study by “Future Market Insights” provides details about the market dynamics affecting the market, Covid-19 Impact, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favorable competitive landscape and trends prevailing over the years.

The global rehabilitation equipment market is expected to expand at a CAGR of 5.2% during the forecast period of 2020 to 2025.

IOL Delivery Systems Market study by “Future Market Insights” provides details about the market dynamics affecting the market, Covid-19 Impact, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favorable competitive landscape and trends prevailing over the years.

Ipsen, a global specialty-driven biopharmaceutical group, publishes its sales performance for the first quarter of 2022.

Basilea Pharmaceutica Ltd. announced that it has entered into a licensing agreement with the U.S.-based company, Fox Chase Chemical Diversity Center, Inc., for a preclinical program on novel first-in-class broad spectrum antifungals with activity against difficult-to-treat mold infections.

Spexis AG announced that its shareholders approved all proposals of the Board of Directors at the 25th Annual General Meeting with a significant majority.

RELIEF THERAPEUTICS Holding SA announced that its wholly owned subsidiary, APR Applied Pharma Research SA, has received a Notice of Allowance from the U.S. Patent and Trademark Office for Patent Application No. 15/303,121 entitled, “Modified Release Orally Administered Amino Acid Formulations.”.

iXensor, the pioneer of mobile health, today announced that Rohto Pharmaceutical Co., Ltd, a multinational pharmaceutical corporation headquartered in Japan, has become the new strategic partner and shareholder.

BioArctic AB’s partner Eisai announced that an article about long-term health outcomes of the investigational anti-amyloid-beta protofibril antibody lecanemab in people living with early Alzheimer’s disease, using disease modeling, was published in the peer-reviewed journal Neurology and Therapy.